Don't sell out safety: a call to preserve risk evaluation and mitigation strategies to reduce harm to patients and the public in the U.S

Journal of Pharmaceutical Policy and Practice
Stacey L Worthy

Abstract

As medicines are becoming more targeted and complex in the U.S., ensuring patients' safe use of medications with known dangerous risks is critical for public health and safety. Therefore, the Risk Evaluation and Mitigation Strategies (REMS) program is more important than ever. The REMS programs mandates that manufacturers utilize tools to manage known or potential serious risks (e.g., death, severe birth defects, prolonged hospitalization) associated with certain drugs while still making these medications available to patients with unmet medical needs. Yet, recently federal policy makers have proposed legislation to force manufacturers to sell medications with known serious risks in a manner that weakens the medications' REMS programs. The author reviewed U.S. legislation, statutes, case law, government agency policies and guidelines, scholarly articles, and news stories published between January 1, 2004 and December 1, 2015 and provided legal and policy analysis. REMS are necessary to make medications with known severe risks available to certain patient populations for whom treatment may not be available otherwise. In order to ensure that proper safety measures are preserved and medications with known risks are not diverted to...Continue Reading

Citations


❮ Previous
Next ❯

Methods Mentioned

BETA
pregnancy test

Software Mentioned

MGA
REMS

Related Concepts

Related Feeds

Birth Defects

Birth defects encompass structural and functional alterations that occur during embryonic or fetal development and are present since birth. The cause may be genetic, environmental or unknown and can result in physical and/or mental impairment. Here is the latest research on birth defects.